NCT01211821已完成1 期
Effect of BMS-914392 on the Pharmacokinetics of Metoprolol and on Heart Rate After Co-administration of BMS-914392 and Metoprolol in Healthy Subjects
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of single dose of metoprolol derived from serial measurements of metoprolol plasma concentrations
研究概览
简要总结
The purpose of the study is to assess the effects of BMS-914392 administration on the pharmacokinetics of a single-dose of metoprolol in healthy subjects.
详细描述
Protocol designed to evaluate the potential for a drug-drug-interaction
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
- •Subjects genotyped as Intermediate, Extensive or Ultra-rapid CYP2D6 metabolizers
- •Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy
排除标准
- •Any significant acute or chronic medical illness.
- •Current or recent (within 3 months of study drug administration) gastrointestinal disease.
- •Current or history of neurological diseases or psychiatric disorders, cardiovascular diseases, and bronchospastic diseases.
- •CYP2D6 poor metabolizers based on genotype
研究组 & 干预措施
metoprolol
Other
Treatment A
干预措施: metoprolol (Drug)
BMS-914392 + metoprolol
Experimental
Treatment B
干预措施: metoprolol (Drug)
BMS-914392 + metoprolol
Experimental
Treatment B
干预措施: BMS-914392 (Drug)
结局指标
主要结局
Pharmacokinetics of single dose of metoprolol derived from serial measurements of metoprolol plasma concentrations
时间窗: Pre-dose and 0.5 Hr, 1 Hr, 1.5 Hr, 2 Hr, 3 Hr, 4 Hr, 6 Hr, 8 Hr, 12 Hr, 24 Hr, and 36 Hr after dosing of metoprolol alone or in combination with BMS-914392
次要结局
- The effect of multiple doses of BMS-914392 on PR, QRS, RR, and QTc intervals derived from serial electrocardiograms (ECGs)(Pre-dose and 0.5 Hr, 1 Hr, 1.5 Hr, 2 Hr, 3 Hr, 4 Hr , 6 Hr, 8 Hr, 12 Hr, 24 Hr after dosing with metoprolol alone or in combination with BMS-914392)
- Number of subjects with adverse events as a measure of safety and tolerability of BMS-914392(Daily)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsRheumatoid ArthritisNCT03262740Bristol-Myers Squibb58
已完成
1 期
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsArthritic PsoriasisPsoriasisInflammatory Bowel DiseasesSystemic Lupus ErythematosusNCT03262727Bristol-Myers Squibb49
已完成
1 期
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsHealthy ParticipantsNCT04249284Bristol-Myers Squibb18
已完成
1 期
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy ParticipantsHealthy VolunteersNCT05932277Bristol-Myers Squibb22
已完成
1 期
A Phase 1 Drug-drug Interaction Study in Healthy VolunteersDrug-drug Interaction StudyNCT02227173Bristol-Myers Squibb20